Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial translation release factor in rescue (MTRFR) is a mitochondrial matrix protein encoded by a nuclear gene and is involved in peptide chain termination within the mitochondrial translation system[1][3][6]. It participates in mitoribosome-associated quality control: together with its partner MTRES1, it acts to resolve translation stalls by ejecting unfinished peptide chains and peptidyl-tRNA from stalled ribosomes, thereby preventing aberrant protein synthesis within mitochondria[1][2][6]. Mutations in MTRFR are linked to severe mitochondrial diseases, including spastic paraplegia 55 and combined oxidative phosphorylation deficiency 7, which feature decreased mitochondrial translation and impaired cellular energy production[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial translation release factor in rescue (MTRFR).